To assess the safety and effectiveness of ezetimibe co-administered with any statin [atorvastatin, rosuvastatin or simvastatin] compared to doubling of current statin daily dose in south Asian Canadians

Trial Profile

To assess the safety and effectiveness of ezetimibe co-administered with any statin [atorvastatin, rosuvastatin or simvastatin] compared to doubling of current statin daily dose in south Asian Canadians

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2011

At a glance

  • Drugs Atorvastatin; Ezetimibe; Rosuvastatin; Simvastatin
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 27 Jul 2011 Planned end date changed from 1 Apr 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
    • 27 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Dec 2009 Schering-Plough merged with Merck-and-Co hence Merck-and-Co added as trial sponsor as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top